Investing.com - Financial Markets Worldwide
Get 40% Off
Get 40% Off
🚨 Volatile Markets? Find Hidden Gems for Serious Outperformance
Find Stocks Now

Cardiff Oncology Inc (CRDF)

NASDAQ
Currency in USD
Disclaimer
4.480
+0.250(+5.91%)
Closed
After Hours
3.970-0.510(-11.384%)

CRDF Comments

Regardless of how this operates in the short term, it's still very undervalued.
I really like this failure, I bought it for $ 3, I hope it will fly into the stratosphere soon!!!
cardiff 100$
about to pop
11.20 soon
To the moon 🚀
Wow its going to gain sooner
Zman Any tips for bull?
No hopes mate
good call👎
 i think its a good buy now
https://seekingalpha.com/article/4400581-first-look-cardiff-oncology
In green! Very important step in the right direction. Price is at +11.45% from yesterdays low!
Higher high and higher low on the daily!
Strong finish! Almost 10% up from todays low at $10.21. Signals further upside $$$
What is your price predictions about today
 Right now it's testing yesterdays closing price. Most important thing today imo is to close above this price - $11.14. If so, I expect further upside. Extremely volatile atm. Impossible to predict but a close above $12 would be super bullish imo.
Price is king, but after reading the clinical results I’m pretty sure this dump is a massive overreaction!
Do you think it could be up coming weeks?
Yes, imo the low is in. My short term target is $14, but could go higher.
Okay thanks mate
Imo low is in at 10.75. Expecting a rebound.
Well, almost I guess;-)
I have no idea should I stop loss
stop loss its exactly what they want from you, to take your loss and buy again.
Time to #BUY !
WTH happened?
nothing, no news, just options expiring 😅
Free fall
Nearing bottom of bullish channel: time to buy!
https://www.biospace.com/article/releases/cardiff-oncology-prices-public-offering-sep-30-2020/
Target 35
where is this price point heading
ask nostradamus
Trovagene and PoC Capital Enter Agreement to Fund Clinical Development of Onvansertib in Metastatic Colorectal Cancer (mCRC) Source: PR Newswire (US) SAN DIEGO, Jan. 29, 2019 /PRNewswire/ -- Trovagene, Inc. (Nasdaq: TROV), a clinical-stage oncology therapeutics company, developing drugs that target cell division (mitosis) for the treatment of leukemias, lymphomas and solid tumor cancers, today announced an agreement with PoC Capital, LLC, to fund clinical development of Onvansertib, Trovagene's first-in-class, 3rdgeneration oral and highly selective Polo-like Kinase 1 (PLK1) inhibitor in a Phase 1b/2 clinical trial in patients with metastatic Colorectal Cancer (mCRC). Trovagene submitted an Investigational New Drug (IND) application and protocol to the FDA on December 19, 2018, and received a "study may proceed" notification from the FDA, 28-days later, on January 16, 2019. The trial will be conducted at two prestigious cancer centers in the U.S.; USC Norris Comprehensive Cancer Cent
San Diego, CA-based TrovaGene Inc. (NASDAQ:TROV) , a molecular diagnostic company, recently announced encouraging data pertaining to its Precision Cancer Monitoring (PCM) technology for both urine and plasma EGFR mutation testing. Notably, the results demonstrated greater detection sensitivity for PCM compared to tissue testing alone. The data will be presented in Vienna, Austria at the 17th World Conference on Lung Cancer.
Trovagene to Present Data from Lead Clinical Program of Onvansertib in Acute Myeloid Leukemia at the 60th American Society of...
news out
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.